Loading...
Loading...
MannKind Corporation
MNKD today announced positive
preliminary results from Study 175, a Phase 3 clinical study of AFREZZA®
(insulin human [rDNA origin]) Inhalation Powder, an investigational,
ultra rapid-acting mealtime insulin therapy administered using
MannKind's next-generation (Gen2) inhaler (also known as the Dreamboat™
inhaler), in patients with type 2 diabetes.
Highlights
AFREZZA combined with oral therapy, compared to oral therapy alone,
showed:
Superior reductions in A1c levels;
Significantly more patients reached A1c target levels;
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in